Pimobendan Vetmedin 5 mg Chewable Tablets for Dogs
Valsts: Lielbritānija
Valoda: angļu
Klimata pārmaiņas: HMA (Heads of Medicines Agencies)
Lietošanas instrukcija
(PIL)
31-08-2013
Produkta apraksts
(SPC)
31-08-2013
Aktīvā sastāvdaļa:
pimobendan 5 mg
Pieejams no:
Boehringer Ingelheim Vetmedica GmbH
ATĶ kods:
QC01CE90
Zāļu forma:
Chewable tablet
Ārstniecības grupa:
pimobendane
Ārstniecības joma:
Dogs
Autorizācija datums:
2012-01-27
Lietošanas instrukcija
1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 5 mg chewable tablets for dogs
(AT, BG, CY, CZ, EE, EL, HU, LV, LT, PL, RO, SI, SK, ES, IS, LI, PT)
[Pimobendan Vetmedica 5 mg chewable tablets for dogs
(BE, FI, FR, IE, IT, LU, NL, SE, UK)
Pimobendan Boehringer Ingelheim Vetmedica GmbH 5 mg chewable tablets for dogs
(NO)
The name ‘the product’ will be used in the Product Information]
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One chewable tablet contains:
ACTIVE SUBSTANCE:
Pimobendan
5 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet
Oval, scored, mottled brown tablets with fine white spots, embossed with Boehringer Ingelheim logo
and P03.
The tablet can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or
valvular insufficiency (mitral and/or tricuspid valve regurgitation).
(See also section 4.9).
4.3
CONTRAINDICATIONS
[The product] is not to be used in hypertrophic cardiomyopathies or in diseases in which an
improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic
stenosis).
Since [the product] is metabolised mainly via the liver, it should not be used in dogs with severe
impairment of liver function (see also 4.7).
3
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE
Izlasiet visu dokumentu
Produkta apraksts
1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 1.25 mg chewable tablets for dogs
(AT, BG, CY, CZ, EE, EL, HU, LV, LT, PL, RO, SI, SK, ES, IS, LI, PT)
[Pimobendan Vetmedica 1.25 mg chewable tablets for dogs
(BE, FI, FR, IE, IT, LU, NL, SE, UK)
Pimobendan Boehringer Ingelheim Vetmedica GmbH 1.25 mg chewable tablets for dogs
(NO)
The name ‘the product’ will be used in the Product Information]
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One chewable tablet contains:
ACTIVE SUBSTANCE:
Pimobendan
1.25 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet.
Oblong, scored, mottled brown tablets with fine white spots, embossed with Boehringer Ingelheim
logo and P01.
The tablet can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or
valvular insufficiency (mitral and/or tricuspid valve regurgitation).
(See also section 4.9).
4.3
CONTRAINDICATIONS
[The product] is not to be used in hypertrophic cardiomyopathies or in diseases in which an
improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic
stenosis).
Since [the product] is metabolised mainly via the liver, it should not be used in dogs with severe
impairment of liver function (see also 4.7).
3
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PREC
Izlasiet visu dokumentu
